Total: $2,393.88M | ||||
Company |
Type Of |
Number Of |
Amount |
Investors; Placement |
| | ||||
Active Biotech |
Rights issue |
5.62S |
SKK169 |
About 98.5% of the shares offered were subscribed to based on subscription rights; the shares were purchased at SEK30 each(7/7) |
Adherex Technologies |
Private |
30.39S |
$8.5 |
The shares were sold at $0.28 each and the three- year warrants are exercisable at $0.35 per share; GlaxoSmithKline plc invested $3M in the deal; Leerink Swann & Co. and Versant Partners Inc. were placement agents (7/20) |
Adventrx |
Private |
10.81S and 10.81W |
$20 |
Investment funds controlled by Carl Icahn led the financing, which also included Viking Global Investors LP; the warrants are exercisable at $2.26 per share; CIBC World Markets was lead placement agent and RBC Capital Markets was co- agent (7/22) |
AspenBio Inc. |
Private placement of stock and warrants |
0.56S and 0.56W |
$0.49 |
The deal was the second closing of a financing that totaled about $3.6M; the five-year warrants are exercisable at $1.35 per share; Westminster Securities Corp. was placement agent (7/12) |
BioDelivery |
Funding agreement |
N/A |
$7 |
Clinical Development Capital LLC will provide up to $7M in funding for Phase III trials of BDSI's BEMA Fentanyl product in exchange for a milestone payment and royalties on product sales (7/18) |
Cel-Sci Corp. |
Private placement of stock and warrants |
1.25S and 0.375W |
$0.5 |
A single investor purchased the stock at $0.40 per share; warrant terms were not disclosed (7/19) |
Cephalon |
Private placement of convertible notes |
N/A |
$120 |
Underwriters exercised their option on another $120M in notes, bringing gross proceeds from the sale to $920M; the 2% notes due 2015 are convertible at $46.70 per common share; the notes were sold from a shelf registration (7/1) |
CV |
Public offering of convertible notes |
N/A |
$19.5 |
Underwriters exercised their option on another $19.5M in notes, bringing total proceeds from the public offering to $149.5M; the 3.25% notes due 2013 are convertible into stock at about $27 per share; underwriters were Lehman Brothers, Merrill Lynch & Co., Citigroup and Deutsche Bank Securities (7/1) |
Cytogen |
Private placement of stock and warrants |
3.1S and 0.776W |
$14 |
Shares in the registered direct offering were sold at $4.50 each; the warrants are exercisable at $6 per share; the deal was made from an existing shelf registration (7/19) |
GeneMedix |
Private placement of stock and warrants |
4.31S and 2.16W |
£0.281 (US$0.5) |
The funding is the second $0.5M taken from a potential total of $10M over three years from funds advised by Southridge Management LLP; the three-year warrants are exercisable at 7.25 pence per share (7/14) |
Genentech |
Private placement of notes |
N/A |
$2B |
Genentech priced $500M of 4.4% notes due 2010, $1B of 4.75% notes due 2015, and $500M of 5.25% notes due 2035 (7/13) |
Isotechnika |
Bought-deal financing |
8.9S |
C$20 (US$16.6) |
A syndicate of underwriters led by GMP Securities Ltd. and including Canaccord Capital Corp., National Bank Financial Inc. and TD Securities Inc. purchased the shares at C$2.25 each; the totals include the exercise of their overallotment option (7/12) |
Labopharm |
Debt financing |
N/A |
$10 |
Hercules Technology Growth Capital Inc. provided an 11.95% loan repayable on July 1, 2008; Hercules also got five-year warrants to purchase 543,104 Labopharm shares at $2.71 each (7/11) |
Neurochem |
Warrants exercise |
2.8S |
C$8.8 (US$7.1) |
Picchio Pharma Inc. exercised a warrant from a July 2002 private placement to purchase 2.8M shares; Picchio Pharma now owns about 26.4% of Neurochem (7/25) |
Novavax Inc. |
Private placement of stock |
4S |
$4 |
The shares were sold from a shelf registration at $1 each; Lane Capital Markets LLC was placement agent (7/5) |
Pharmacopeia |
Private placement of stock |
2.47S |
$8.47 |
The shares were sold at $3.43 each, a 15% discount to a five-day average; Jefferies & Co. Inc. was the placement agent (7/28) |
ReGen |
Private placement of stock and warrants |
13.9S and 3.48W |
$11.8 |
The shares were sold at $0.85 each; the five-year warrants are exercisable at $1 per share (7/15) |
Sirna |
Private placement of stock and warrants |
17.5S and |
$28 |
The shares were sold at $1.60 each and the warrants are exercisable at $1.92 per share until July 2010; investors included Sprout Group, Oxford Bioscience Partners and Venrock Associates; Thomas Weisel Partners was placement agent, and Leerink Swann and Brean Murray were co-advisers (7/7) |
Solexa |
Private placement of stock and warrants |
6S and 3W |
$24 |
The financing was the second closing of a $32.5M round; the first part closed in April; the shares were sold at $4 each and the warrants are exercisable at $5 each; investors included Abingworth Management Ltd., Amadeus Capital Partners Ltd., Oxford Bioscience Partners and SV Life Sciences; SG Cowen & Co. LLC was placement agent (7/12) |
SR Pharma |
Private placement of stock |
36.1S |
£8.3 (US$14.6) |
Separately, Introgen Therapeutics Inc. invested $3M in SR Pharma as part of a collaboration; Mulier Capital Ltd. was financial adviser for the placement (7/28) |
Stem Cells |
Private placement of stock |
6.2S |
£6 (US$10.5) |
Stem Cells gained a public listing on the Alternative Investment Market in the financing; Collins Stewart plc brokered the deal (7/14) |
Synthetic |
Private placement of convertible debt and warrants |
N/A and 8.4W |
$1.85 |
Terms of the convertible debentures were not disclosed; the three-year warrants are exercisable at $0.242 per share; the investment was led by Palisades Master Fund and arranged by HPC Capital Management LLC (7/13) |
Transgene SA |
Private placement of stock and warrants |
4.66S and 2.33W |
€34.9 (US$42.2) |
Most of the shares were placed in Europe; the one- year warrants are exercisable at €8.05 per share (7/11) |
Xenomics Inc. |
Private placement of convertible stock and warrants |
N/A and 0.387W |
$2.77 |
The Series A convertible stock is convertible into common stock at $2.15 per share; the five-year warrants are exercisable at $3.25 per share (7/15) |
Notes: | ||||
This chart does not include real estate or manufacturing plant financings. | ||||
# Unless otherwise indicated, shares are traded on the Nasdaq exchange. | ||||
Currency conversions are based on exchange rates at the time of the deal. | ||||
N/A = Not applicable; ND = Not disclosed. | ||||
AIM = Alternative Investment Market; AMEX = American Stock Exchange; LSE = London Stock Exchange; NYSE = New York Stock Exchange; OTC BB = Over-the-Counter Bulletin Board; SSE = Stockholm Stock Exchange; TSE = Toronto Stock Exchange. | ||||
